Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study.

OBJECTIVES This study examined the prevalence of nonadherence with oral hypoglycemic agents, antihypertensive drugs (angiotensin-converting enzyme inhibitors [ACEIs] and angiotensin II receptor blockers [ARBs]), and statin medications among Medicare Part D enrollees with diabetes and analyzed the potential demographic and clinical factors that predict medication nonadherence. METHODS This was a retrospective cohort study of Medicare Part D enrollees with diabetes from 6 states (Alabama, California, Florida, Mississippi, New York, and Ohio). Adherence was calculated as the proportion of days covered (PDC; number of days with medication on hand/number of days in the specified time interval). A PDC was derived for each of the 3 categories of medications for patients who had at least 1 claim for the same class of medication. A comorbidity measure was created for each beneficiary using the Deyo-adapted Charlson Comorbidity Index (CCI). Associations between nonadherence and patient characteristics including age, sex, race/ethnicity, and Deyo-adapted CCI were examined. Logistic regression models were constructed to identify predictors of nonadherence. RESULTS The study included 1,888,682 patients with diabetes. The mean (SD) age was 71.6 (11.6) years, and 59.5% (1,123,220/1,888,682) were female. A total of 66.4% (1,254,538/1,888,682) were white, 16.3% (308,158/1,888,682) were black, and 7.8% (147,498/1,888,682) were Hispanic. Estimated rates of non-adherence for oral hypoglycemic agents, ACEIs/ARBs, and statins were 35.1% (386,666/1,101,533), 41.8% (449,561/1,075,285), and 46.4% (447,106/962,877), respectively. In unadjusted analyses, patients aged <65 years, women, black or Hispanic patients, and patients with higher Deyo-adapted CCI were more likely to be nonadherent to all 3 classes of medications. The results were consistent in multivariate analyses, and all results were statistically significant at P < 0.001. CONCLUSIONS In this study of Medicare Part D enrollees with diabetes, patients aged <65 years, women, black or Hispanic patients, and those with higher comorbidity scores were more likely to be nonadherent to medications. Interventions should be developed to improve medication adherence among these subgroups so that patients can achieve the full benefits of prescribed pharmacologic therapies.

[1]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  Timothy W. Smith,et al.  Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[4]  J. Steiner,et al.  A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.

[5]  M. Joffres,et al.  Medication Persistence Rates and Factors Associated with Persistence in Patients Following Stroke: A Cohort Study , 2008, BMC neurology.

[6]  L Keoki Williams,et al.  Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. , 2004, Diabetes care.

[7]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[8]  A. Rodday,et al.  Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. , 2007, Health affairs.

[9]  Richard H. Chapman,et al.  Predictors of adherence with antihypertensive and lipid-lowering therapy. , 2005 .

[10]  B. Hoogwerf,et al.  Managing type 2 diabetes: going beyond glycemic control. , 2015, Journal of managed care pharmacy : JMCP.

[11]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[12]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[13]  J. Tjia,et al.  Will the Medicare Prescription Drug Benefit Eliminate Cost Barriers for Older Adults with Diabetes Mellitus? , 2006, Journal of the American Geriatrics Society.

[14]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[15]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.

[16]  F. Camacho,et al.  Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. , 2003, Clinical therapeutics.

[17]  David B Lawrence,et al.  Relationship of Oral Antihyperglycemic (Sulfonylurea or Metformin) Medication Adherence and Hemoglobin A1c Goal Attainment for HMO Patients Enrolled in a Diabetes Disease Management Program , 2006, Journal of managed care pharmacy : JMCP.

[18]  Denys T. Lau,et al.  Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. , 2004, Diabetes care.

[19]  J. Cramer A Systematic Review of Adherence With Medications for Diabetes , 2004 .

[20]  D. Meltzer,et al.  The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures , 2008, Annals of Internal Medicine.

[21]  Michael M. Engelgau,et al.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.

[22]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[23]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[24]  J. Cramer A systematic review of adherence with medications for diabetes. , 2004, Diabetes care.

[25]  Jennifer Y. Liu,et al.  Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes , 2004, Journal of General Internal Medicine.

[26]  J. Dora,et al.  Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.

[27]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[28]  Lawrence O Gostin,et al.  Health information privacy. , 1995, Cornell law review.

[29]  R. Rubin,et al.  Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. , 2005, The American journal of medicine.

[30]  P Michael Ho,et al.  Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. , 2008, American heart journal.

[31]  Peter J. Neumann,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[32]  Michael L. Johnson,et al.  Patterns of antihypertensive therapy among patients with diabetes , 2005, Journal of General Internal Medicine.

[33]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[34]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[35]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[36]  K. Bennett,et al.  A review of studies of adherence with antihypertensive drugs using prescription databases , 2005, Therapeutics and clinical risk management.

[37]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[38]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[39]  C. Cooke,et al.  Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. , 2015, Journal of managed care pharmacy : JMCP.

[40]  D. Grobbee,et al.  Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. , 2001, Diabetes care.

[41]  V. Basevi Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[42]  Femida Gwadry-Sridhar,et al.  A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[43]  D. S. Gochman,et al.  Handbook of health behavior research , 1997 .

[44]  I. Lerman Adherence to treatment: the key for avoiding long-term complications of diabetes. , 2005, Archives of medical research.

[45]  Won Chan Lee,et al.  Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings , 2005, Journal of managed care pharmacy : JMCP.

[46]  Yelena Rozenfeld,et al.  Oral antidiabetic medication adherence and glycemic control in managed care. , 2008, The American journal of managed care.

[47]  A. Unger,et al.  Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. , 2005, Clinical therapeutics.

[48]  K. Secnik,et al.  Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. , 2007, Clinical therapeutics.